Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

INCB028050

Known as: INCB 028050 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2013
2013
Background LY3009104 (LY) is a novel, oral inhibitor of the JAK1/JAK2 signalling pathway known to be important in the… Expand
Is this relevant?
2013
2013
Janus kinase (JAK) inhibitors have been developed as anti-inflammatory agents and have demonstrated clinical efficacy in… Expand
Is this relevant?
Review
2013
Review
2013
The Janus Kinase (JAK) group of tyrosine kinases are intracellular signaling molecules which become phosphorylated upon… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases… Expand
Is this relevant?
2010
2010
Discovery of Th 17 cells Until about a decade ago, many human autoimmune diseases and the corresponding experimental animal… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?